Printer Friendly

LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional Assay.

M2 PHARMA-May 22, 2019-LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional Assay

(C)2019 M2 COMMUNICATIONS

- US-based LineaRx, a subsidiary of molecular technologies company Applied DNA Sciences, Inc. (NASDAQ: APDN), is in process of designing new, custom amplicons for an existing customer in the in vitrodiagnostics market, the company said.

This diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing revenue from an existing supply agreement.

LineaRx currently receives annual orders for large-scale DNA from this customer under a five-year supply agreement executed in 2017.

The second annual purchase under the supply agreement was received earlier this year, and shipments will commence this quarter and continue for the following three quarters.

This purchase order yields revenue in excess of USD 500,000.

LineaRx believes linear DNA is ideal for diagnostic applications in that modifications to the target amplicon made through the PCR process are faster, more efficient and less costly than traditional chemical derivatization.

LineaRx seeks to commercialise the biotherapeutic value of Applied DNA's deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction.

Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health.

In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA.

These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 22, 2019
Words:328
Previous Article:Ocular Therapeutix Releases Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma.
Next Article:US Merck Provides Update on Phase 3 KEYNOTE-119 Study of Keytruda Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast...
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters